Vivo Surgical’s KLARO™ In vivo Lighting Device Provides Unparalleled Illumination of Surgical Cavities

Vivo Surgical’s KLARO™ in vivo lighting device is designed to revolutionize surgical illumination and provide a clearer view of surgical cavities. Developed in partnership with SingHealth – Singapore’s largest group of healthcare institutions – and Panasonic Lighting (Europe), this innovative LED light solution solves many of the problems associated with traditional operating theatre lighting and personal headlights.

Inadequate surgical lighting has been identified as one of the key challenges in operating theatres, particularly in complex open procedures involving deep or narrow surgical cavities. KLARO is designed specifically to eliminate this issue, giving a better view of the surgical site while eliminating the ergonomic problems associated with headtorches. The flexible LED tip offers four lighting intensities, with a compact, 4.6 mm diameter to make it easy to position during surgery, ensuring wide-angle illumination.

The single-use KLARO has been developed specifically for surgical use, offering up to four hours of consistent in vivo illumination while maintaining a safe operating temperature of below 38 °C/100°F. The FDA registered, CE certified device clips easily onto surgical drapes, with a long light strip to allow effective hands-free positioning of the light within the surgical cavity. It can also be used to transform any existing surgical retractor into a lit one using the supplied silicone retractor loops, offering seamless integration with existing instruments to minimize workflow disruption. This innovative, cost-effective solution – which is already being used in oncology, gynaecology, head and neck, and general surgery in over 20 countries – is helping to improve patient outcomes and accelerate recovery times by minimizing the size of surgical incisions, as well as relieving eye fatigue and ergonomic issues faced by surgeons.

As a clinician-driven company, Vivo Surgical is always looking to further expand the application of its novel lighting solutions, and is keen to enter into new collaborative ventures and distribution partnerships worldwide. In particular, the company is currently seeking partners with expertise in operating room consumables.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy